Cite
HARVARD Citation
Wells, A. et al. (2020). Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet. 8 (5), pp. 453-460. [Online].